search
Back to results

Protecting Pregnant Women From Infectious Diseases

Primary Purpose

Influenza, Pertussis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
P3 Vaccine Promotion Package.
Sponsored by
Emory University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Influenza focused on measuring Influenza, Pertussis, Vaccination

Eligibility Criteria

18 Years - 50 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Between the ages of 18 - 50
  • Currently pregnant
  • Unvaccinated with 2012 - 2013 seasonal influenza vaccine
  • Unvaccinated with Tdap vaccine during current pregnancy

Exclusion Criteria:

  • Under 18 years of age or over 50
  • Not currently pregnant
  • Previous receipt of 2012 - 2013 seasonal influenza vaccine
  • Previous receipt of Tdap vaccine during current pregnancy
  • Does not speak English

Sites / Locations

  • Athens OBGYN
  • Women's Healthcare Associates
  • Emory Clinic A, Clifton Road Clinic
  • Women's Center of Athens
  • North Pointe OB/GYN
  • Southern Crescent Women's Health Care
  • W.T. Anderson Health Center - MCCG
  • My OB/GYN
  • New Millennium OB/GYN
  • Statesboro OB/GYN Specialists
  • Shaw Center for Women's Health

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

P3 Vaccine Promotion Package

No P3 vaccine promotion package intervention

Arm Description

The 5 obstetric practices randomized to the intervention arm will receive and implement all components of the evidence-based P3 vaccine promotion package at the beginning of the study.

The 5 obstetric practices randomized to the control arm will not receive the comprehensive vaccine promotion package at the beginning of the study and will instead be instructed to continue their standard of care regarding influenza and Tdap vaccination of pregnant patients.

Outcomes

Primary Outcome Measures

Receipt of influenza vaccine during pregnancy
Our primary outcome is receipt of a 2012 - 2013 seasonal influenza vaccine during a participant's current pregnancy, before she delivers her child(ren).

Secondary Outcome Measures

Receipt of Tdap vaccine during pregnancy
A secondary outcome is receipt of a Tdap vaccine during a participant's current pregnancy, before she delivers her child(ren).

Full Information

First Posted
December 18, 2012
Last Updated
October 30, 2015
Sponsor
Emory University
Collaborators
Centers for Disease Control and Prevention
search

1. Study Identification

Unique Protocol Identification Number
NCT01761799
Brief Title
Protecting Pregnant Women From Infectious Diseases
Official Title
Protecting Pregnant Women From Infectious Diseases: a Cluster Randomized Evaluation of the Comprehensive "P3" Intervention Package Within Obstetric Practices in Georgia
Study Type
Interventional

2. Study Status

Record Verification Date
October 2015
Overall Recruitment Status
Completed
Study Start Date
December 2012 (undefined)
Primary Completion Date
February 2014 (Actual)
Study Completion Date
August 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Emory University
Collaborators
Centers for Disease Control and Prevention

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary research aim of this project is to test the effectiveness of a comprehensive, evidence-based vaccine promotion package implemented in the obstetric setting on increasing the likelihood that a pregnant woman in Georgia will receive an influenza and/or pertussis vaccine.
Detailed Description
The primary research aim of this project is to test the effectiveness of a comprehensive, evidence-based vaccine promotion package implemented in the obstetric setting on increasing the likelihood that a pregnant woman in Georgia will receive an influenza vaccine and/or Tdap vaccine before delivery. A secondary research aim assesses whether the comprehensive package improves maternal knowledge, attitudes, and beliefs regarding maternal and infant vaccination. The intervention package will include evidence-based components aimed at the practice-level, provider-level, and patient level and will be tested through a cluster-randomized trial design. The primary outcome measure is influenza vaccine receipt during pregnancy. The secondary outcomes include 1) receipt of pertussis (Tdap) vaccination during pregnancy, and 2) changes in maternal knowledge, attitudes and beliefs regarding maternal and infant vaccination. The primary hypothesis is that implementation of a comprehensive vaccine promotion package in the obstetric setting will increase the likelihood that a pregnant woman receives an influenza and/or pertussis vaccination.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza, Pertussis
Keywords
Influenza, Pertussis, Vaccination

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
330 (Actual)

8. Arms, Groups, and Interventions

Arm Title
P3 Vaccine Promotion Package
Arm Type
Experimental
Arm Description
The 5 obstetric practices randomized to the intervention arm will receive and implement all components of the evidence-based P3 vaccine promotion package at the beginning of the study.
Arm Title
No P3 vaccine promotion package intervention
Arm Type
No Intervention
Arm Description
The 5 obstetric practices randomized to the control arm will not receive the comprehensive vaccine promotion package at the beginning of the study and will instead be instructed to continue their standard of care regarding influenza and Tdap vaccination of pregnant patients.
Intervention Type
Behavioral
Intervention Name(s)
P3 Vaccine Promotion Package.
Intervention Description
"P3" stands for Practice, Provider, and Patient level vaccine promotion package. The 5 obstetric practices randomized to the intervention arm will receive this comprehensive influenza and Tdap vaccine promotion package at the beginning of the study. Physicians and staff will be familiarized with each component, and practices will be instructed to implement each component to the best of their ability. The components include: posters, educational brochures, lapel buttons, provider-to-patient talking points, lists of nearby locations offering flu and/or Tdap vaccines (if not offered by the practice), identification of a "vaccine champion" within the practice, provider and staff training on vaccination during pregnancy, and use of an interactive, tablet-based educational tutorial for patients.
Primary Outcome Measure Information:
Title
Receipt of influenza vaccine during pregnancy
Description
Our primary outcome is receipt of a 2012 - 2013 seasonal influenza vaccine during a participant's current pregnancy, before she delivers her child(ren).
Time Frame
Participants will be followed for the remaining duration of their pregnancy, which will range from approximately 2 weeks to 7 months depending upon their gestation at enrollment.
Secondary Outcome Measure Information:
Title
Receipt of Tdap vaccine during pregnancy
Description
A secondary outcome is receipt of a Tdap vaccine during a participant's current pregnancy, before she delivers her child(ren).
Time Frame
Participants will be followed for the remaining duration of their pregnancy, which will range from approximately 2 weeks to 7 months depending upon their gestation at enrollment.
Other Pre-specified Outcome Measures:
Title
Changes in maternal knowledge, attitudes and beliefs regarding maternal and infant vaccination
Description
This secondary outcome will be assessed through two surveys: one survey administered at baseline upon enrollment, and another survey administered 2 - 3 months post-partum.
Time Frame
Participants will be followed for the remaining duration of their pregnancy, which will range from approximately 2 weeks to 7 months depending upon their gestation at enrollment.

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Between the ages of 18 - 50 Currently pregnant Unvaccinated with 2012 - 2013 seasonal influenza vaccine Unvaccinated with Tdap vaccine during current pregnancy Exclusion Criteria: Under 18 years of age or over 50 Not currently pregnant Previous receipt of 2012 - 2013 seasonal influenza vaccine Previous receipt of Tdap vaccine during current pregnancy Does not speak English
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Saad B Omer, MBBS,MPH,PhD
Organizational Affiliation
Emory Unversity
Official's Role
Principal Investigator
Facility Information:
Facility Name
Athens OBGYN
City
Athens
State/Province
Georgia
ZIP/Postal Code
30606
Country
United States
Facility Name
Women's Healthcare Associates
City
Athens
State/Province
Georgia
ZIP/Postal Code
30606
Country
United States
Facility Name
Emory Clinic A, Clifton Road Clinic
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Women's Center of Athens
City
Bogart
State/Province
Georgia
ZIP/Postal Code
30622
Country
United States
Facility Name
North Pointe OB/GYN
City
Cumming
State/Province
Georgia
ZIP/Postal Code
30041
Country
United States
Facility Name
Southern Crescent Women's Health Care
City
Fayetteville
State/Province
Georgia
ZIP/Postal Code
30214
Country
United States
Facility Name
W.T. Anderson Health Center - MCCG
City
Macon
State/Province
Georgia
ZIP/Postal Code
31201
Country
United States
Facility Name
My OB/GYN
City
Riverdale
State/Province
Georgia
ZIP/Postal Code
30274
Country
United States
Facility Name
New Millennium OB/GYN
City
Riverdale
State/Province
Georgia
ZIP/Postal Code
30274
Country
United States
Facility Name
Statesboro OB/GYN Specialists
City
Statesboro
State/Province
Georgia
ZIP/Postal Code
30458
Country
United States
Facility Name
Shaw Center for Women's Health
City
Thomasville
State/Province
Georgia
ZIP/Postal Code
31792
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
26044495
Citation
Chamberlain AT, Seib K, Ault KA, Rosenberg ES, Frew PM, Cortes M, Whitney EA, Berkelman RL, Orenstein WA, Omer SB. Improving influenza and Tdap vaccination during pregnancy: A cluster-randomized trial of a multi-component antenatal vaccine promotion package in late influenza season. Vaccine. 2015 Jul 9;33(30):3571-9. doi: 10.1016/j.vaccine.2015.05.048. Epub 2015 Jun 1.
Results Reference
result
PubMed Identifier
27082036
Citation
Chamberlain AT, Seib K, Ault KA, Rosenberg ES, Frew PM, Cortes M, Whitney EA, Berkelman RL, Orenstein WA, Omer SB. Impact of a multi-component antenatal vaccine promotion package on improving knowledge, attitudes and beliefs about influenza and Tdap vaccination during pregnancy. Hum Vaccin Immunother. 2016 Aug 2;12(8):2017-2024. doi: 10.1080/21645515.2015.1127489. Epub 2016 Apr 15.
Results Reference
derived

Learn more about this trial

Protecting Pregnant Women From Infectious Diseases

We'll reach out to this number within 24 hrs